HLS Therapeutics
- Company typePublic
- Founded2015
- HeadquartersCaledon, Canada
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
HLS Therapeutics firmographics
Firmographics- Name
- HLS Therapeutics
- Legal name
- HLS Therapeutics Inc.
- Website
- https://hlstherapeutics.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
HLS Therapeutics industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Offices of Mental Health Practitioners (except Physicians) (621330)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where HLS Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Caledon
- HQ country
- Canada
- HQ region
- North America
Offices5 records
Markets served
HLS Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D
Revenue model
- Pharmaceutical Product Sales: HLS generates revenue through the sale of branded pharmaceutical products including CLOZARIL (clozapine) for treatment-resistant schizophrenia and VASCEPA (icosapent ethyl) for cardiovascular risk reduction. Product sales are generated from both Canadian and U.S. markets.
- Royalties: The company receives royalty revenue from its royalty portfolio, which includes multiple indications and is marketed by third parties. Royalty revenue was $0.25 million in Q1 2026.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
HLS Therapeutics product offering
Product offeringCore offering
HLS Therapeutics acquires, in-licenses, and commercializes branded pharmaceutical products across North America, focused on two therapeutic areas: psychiatric disorders led by CLOZARIL (clozapine) for treatment-resistant schizophrenia, and cardiovascular disease anchored by VASCEPA (icosapent ethyl) for cardiovascular risk reduction and the newly launched NILEMDO (bempedoic acid) for LDL-cholesterol reduction. The company supports these therapies with the CSAN Pronto point-of-care diagnostic for CLOZARIL patient monitoring and the MyCare Psychiatry therapeutic drug monitoring service, distributing through specialty pharmacy programs and payer/reimbursement channels.
Product overview
HLS Therapeutics is a pharmaceutical company focused on the acquisition and commercialization of branded medicines in North America. The company's product portfolio centers on two therapeutic areas: psychiatric disorders (CLOZARIL for treatment-resistant schizophrenia, supported by CSAN Pronto diagnostics and MyCare Psychiatry monitoring services) and cardiovascular disease (VASCEPA for CV risk reduction, and the newly launched NILEMDO and upcoming NEXLIZET for LDL-cholesterol reduction). The company also holds a royalty portfolio of products marketed by third parties globally. The core portfolio strategy involves in-licensing or acquiring late-stage and commercial-stage pharmaceutical products, ensuring regulatory compliance with FDA and Health Canada, and providing reliable market access.
Differentiator
Problem solved
Functional benefit
Brands
- VASCEPA: Cardiovascular risk reduction product (icosapent ethyl) marketed in Canada
- NILEMDO
- CLOZARIL
- CSAN Pronto
- MyCare Psychiatry
Products and services
- CLOZARIL (clozapine) Treatment-resistant schizophrenia medication marketed in both the United States and Canada. Requires blood monitoring through the CSAN Pronto system.
- VASCEPA (icosapent ethyl) Cardiovascular risk reduction therapy marketed in Canada. EPA-based treatment for cardiovascular and cardiometabolic conditions.
- NILEMDO (bempedoic acid) First-in-class, once-daily oral non-statin therapy for reducing LDL-cholesterol in patients at risk of cardiovascular disease who cannot reach LDL-C goals on statin therapy or who are statin intolerant.
- NEXLIZET (bempedoic acid/ezetimibe) Bempedoic acid and ezetimibe combination therapy for cardiovascular risk reduction, in-licensed from Esperion Therapeutics with Canadian commercial launch expected in 2027.
- CSAN Pronto
Quantifiable outcome
- Vascepa net sales increased 15% to $4.8 million in Q1 2026, with 18% unit growth reflecting sustained demand
- +4 more outcomes
Companies that use HLS Therapeutics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
HLS Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
HLS Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- AmarinminorHLS Therapeutics and Amarin collaborated to present scientific data on VASCEPA and EPA (eicosapentaenoic acid) at the Canadian Cardiovascular Congress in October 2025. The collaboration focused on clinical and mechanistic benefits of icosapent ethyl (IPE) for cardiovascular and cardiometabolic conditions, emphasizing ongoing research and the commercial availability of VASCEPA in Canada.
- Esperion TherapeuticscoreHLS Therapeutics in-licensed exclusive Canadian rights to NILEMDO (bempedoic acid) and NEXLIZET from Esperion Therapeutics in May 2025. NILEMDO received Health Canada approval in November 2025 and was commercially launched in Canada in March 2026. This partnership significantly expands HLS's cardiovascular portfolio and represents a potential franchise that could more than double company revenue.
- Health Products Stewardship Association (HPSA)minorHLS Therapeutics supports Medications Return Programs managed by the Health Products Stewardship Association (HPSA), which provide safe and convenient disposal of unused or expired medications in an environmentally responsible manner.
- Health StewardsminorPartnership with Health Stewards organization to support medication return programs and proper disposal of pharmaceutical products.
Scale indicators12 records
Recent moves6 records
Expansion highlights5 records
HLS Therapeutics competitors and assessment
Company assessmentDirect peers
- Jazz Pharmaceuticals: Specialty pharmaceutical company with a defined CNS franchise (Xywav, Epidiolex, Sunosi) that follows a similar branded/specialty pharma growth model, commercializing differentiated CNS products in North America with established sales infrastructure.
- Amarin Corporation: Cardiovascular-focused specialty pharma behind VASCEPA (icosapent ethyl), the same molecule HLS commercializes in Canada; HLS partners directly with Amarin on Canadian cardiovascular launches and scientific exchange programs.
- Supernus Pharmaceuticals: Specialty CNS pharma company selling branded neurology/psychiatry products (e.g., Trokendi XR, Oxtellar XR) through a focused field force, closely matching HLS's branded-pharma-stewardship model in psychiatry/neurology.
- H. Lundbeck: Global specialty pharmaceutical company focused on brain diseases (psychiatry and neurology) including branded CNS products, serving a similar prescriber base of psychiatrists and neurologists with branded specialty therapeutics.
- Esperion Therapeutics: Originator of NILEMDO (bempedoic acid) and NEXLIZET, whose exclusive Canadian rights were in-licensed to HLS in May 2025; comparable specialty CV pharma commercializing the same franchise in different geographies.
Others
- Corbus Pharmaceuticals: Specialty pharma where HLS's CEO Craig Millian and CCO Brian Walsh previously held senior leadership roles (COO and VP Corp Dev/Commercial respectively); provides talent/operating-model comparability rather than direct product overlap.
Broad incumbents
- Endo International: Specialty pharmaceutical company with branded and generic CNS, CV and pain products; a broad incumbent whose branded specialty portfolio includes therapeutic areas adjacent to HLS's CNS and CV focus.
- Bausch Health: Large diversified specialty pharma with branded CNS, CV, and other specialty product portfolios; offers a much broader incumbent footprint but overlaps with HLS on branded specialty strategy and post-exclusivity lifecycle management.
- Purdue Pharma: Long-standing specialty CNS pharmaceutical company marketing branded central nervous system therapies; comparable prescriber targets and lifecycle brand approach to HLS's CLOZARIL and MyCare Psychiatry offerings.
Emerging players
- Intra-Cellular Therapies: Emerging CNS specialty pharma behind Caplyta (lumateperone), focused on psychiatry indications including treatment-resistant populations; overlaps with HLS's CNS specialty commercial model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
HLS Therapeutics social profiles
Digital presenceHLS Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
HLS Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
HLS Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
HLS Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HLS Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HLS Therapeutics
What does HLS Therapeutics do?
HLS Therapeutics acquires, in-licenses, and commercializes branded pharmaceutical products across North America, focused on two therapeutic areas: psychiatric disorders led by CLOZARIL (clozapine) for treatment-resistant schizophrenia, and cardiovascular disease anchored by VASCEPA (icosapent ethyl) for cardiovascular risk reduction and the newly launched NILEMDO (bempedoic acid) for LDL-cholesterol reduction. The company supports these therapies with the CSAN Pronto point-of-care diagnostic for CLOZARIL patient monitoring and the MyCare Psychiatry therapeutic drug monitoring service, distributing through specialty pharmacy programs and payer/reimbursement channels.
Is HLS Therapeutics a public or private company?
HLS Therapeutics is a public company. It is classified as public and is currently operating.
When was HLS Therapeutics founded?
HLS Therapeutics was founded in 2015. It employs 51 to 100 people.
Where is HLS Therapeutics based?
HLS Therapeutics is headquartered in Caledon, Canada, in the North America region.
How does HLS Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are royalties.
Who are HLS Therapeutics's main competitors?
Direct peers on record are Jazz Pharmaceuticals, Amarin Corporation, Supernus Pharmaceuticals, H. Lundbeck and Esperion Therapeutics. Corbus Pharmaceuticals is listed as an others. Broad incumbents are Endo International, Bausch Health and Purdue Pharma. Intra-Cellular Therapies is listed as an emerging player.
Does HLS Therapeutics have an API?
No public API is recorded for HLS Therapeutics.
What industry is HLS Therapeutics in?
HLS Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 621330 and its SIC code is 2834.